Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Svitla Systems Acquires Australia’s Kiandra IT to Expand Global Engineering Footprint and Accelerate AI-Driven Delivery

April 30, 2026

Tylosin Market Research Report 2026: $1 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

April 30, 2026

Carney, ministers say IRGC members barred from Canada after visa granted

April 30, 2026

Tuck Tape Expands Presence in Canadian Consumer Market with New and Rebranded Product Lineup

April 30, 2026

Biologics Outsourcing Market Research Report 2026: $42.43 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

April 30, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » ROOT Brands® Addresses the GLP-1 Gap with CRUSH and SCULPT, a Science-Driven Protocol for Metabolic and Muscle Support After Ozempic® and Wegovy®
Press Release

ROOT Brands® Addresses the GLP-1 Gap with CRUSH and SCULPT, a Science-Driven Protocol for Metabolic and Muscle Support After Ozempic® and Wegovy®

By News RoomApril 8, 20264 Mins Read
ROOT Brands® Addresses the GLP-1 Gap with CRUSH and SCULPT, a Science-Driven Protocol for Metabolic and Muscle Support After Ozempic® and Wegovy®
Share
Facebook Twitter LinkedIn Pinterest Email

Franklin, TN, April 08, 2026 (GLOBE NEWSWIRE) — ROOT Brands®, a science-driven wellness company led by Chief Science Officer Dr. Christina Rahm and Chief Executive Officer Clayton Thomas, today announced the strategic positioning of CRUSH™ and SCULPT™ as a targeted nutritional protocol designed to support individuals during and after GLP‑1 medication use.

This announcement addresses a rapidly emerging concern among practitioners, researchers, and consumers alike—what is increasingly referred to as the “GLP‑1 gap.” This gap reflects the metabolic, muscular, and cellular support needs that pharmaceutical appetite-suppressing medications were not designed to address.

GLP‑1 receptor agonists such as Ozempic® and Wegovy® have significantly altered the weight management landscape, driving widespread adoption and clinical attention. As utilization continues to rise, so does awareness of common post-use challenges, including reduced metabolic efficiency, loss of lean body mass, digestive discomfort, low energy levels, and weight regain after discontinuation. ROOT Brands developed CRUSH and SCULPT to provide nutritional support at precisely this stage of the wellness journey.

“GLP‑1 medications can start the journey, but they were never intended to complete it,” said Dr. Christina Rahm, Chief Science Officer of ROOT Brands®. “Long-term results require metabolic, muscular, and cellular support that goes beyond appetite suppression. CRUSH and SCULPT were created to help meet those needs.”


Understanding the GLP‑1 Gap: What Medications Leave Unaddressed

GLP‑1 receptor agonists function primarily by suppressing appetite, slowing gastric emptying, and supporting blood sugar regulation. Their role in short-term weight loss is well documented. However, these medications are not formulated to preserve lean muscle mass, enhance cellular energy production, or support long-term metabolic adaptability—factors that play a critical role in maintaining results beyond active medication use.

Clinical observation and consumer feedback frequently identify a consistent pattern following GLP‑1 discontinuation: appetite returns quickly, resting metabolic rate may decline, and lean muscle mass may be reduced. Without supportive nutritional strategies, weight regain is common and may occur rapidly. CRUSH and SCULPT were developed to help address these challenges through ingredient-focused, cellular-level nutritional support.


About the CRUSH™ and SCULPT™ Protocol

CRUSH™ is formulated with seven essential amino acids and is designed to support healthy metabolic function, cellular energy processes, and natural fat utilization. The stimulant-free formulation is positioned to complement recovery, metabolic efficiency, and daily energy needs without pharmaceutical dependency.

SCULPT™ is designed as a plant-based nutritional support formula, incorporating clinically studied ingredients such as InnoSlim®, along with Gymnema Sylvestre, White Kidney Bean extract, and Valerian Root. The formulation focuses on lean muscle support, body composition balance, strength preservation, and metabolic resilience.

Together, CRUSH and SCULPT follow ROOT Brands’ cellular-first philosophy, summarized as:

Clean the cell.
Feed the cell.
Protect the cell.

By supporting efficient nutrient utilization, cellular health, and mitochondrial function, the protocol is designed for:

  • Individuals currently using GLP‑1 medications who want to support lean muscle and metabolic health
  • Individuals transitioning off GLP‑1 medications seeking a non-pharmaceutical nutritional approach
  • Individuals pursuing long-term body composition and metabolic support without injectable therapies

“Search trends and consumer behavior make it clear—people recognize that something is missing after GLP‑1,” said Clayton Thomas, CEO of ROOT Brands®. “CRUSH and SCULPT were developed to support that moment and provide a structured, science-driven answer.”


About ROOT Brands®

ROOT Brands® is a Franklin, Tennessee–based wellness company committed to science-driven, cellular-first nutrition solutions. Led by Chief Science Officer Dr. Christina Rahm and CEO Clayton Thomas, the company develops products grounded in ingredient research, transparent sourcing, and the belief that sustainable health begins at the cellular level.

The ROOT Brands® product portfolio includes CRUSH™, SCULPT™, Clean Slate™, Zero‑In™, Restore™, and additional wellness solutions distributed through a global network of independent brand partners.

Check out this interview with Dr. April Spenser and Clayton Thomas

            
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Svitla Systems Acquires Australia’s Kiandra IT to Expand Global Engineering Footprint and Accelerate AI-Driven Delivery

Tylosin Market Research Report 2026: $1 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Tuck Tape Expands Presence in Canadian Consumer Market with New and Rebranded Product Lineup

Biologics Outsourcing Market Research Report 2026: $42.43 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

TTEC Recognized as a Major Contender in Everest Group’s 2026 Healthcare CXM Intelligent Operations PEAK Matrix® Assessment

Pharmaceutical API Manufacturing Market Research Report 2026: $347.49 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Topical Drugs Contract Development and Manufacturing Organization (CDMO) Market Research Report 2026: $121 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts 2020-2035

MAGIC by Informa in Nashville Brings Southern Flair to Music City Center with Fresh Trends, Local Talent, and Retail Insights

Why Regulators Trust CoreFiling: The Case for Expert-Backed Data Infrastructure in an Era of Increasing Scrutiny

Editors Picks

Tylosin Market Research Report 2026: $1 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

April 30, 2026

Carney, ministers say IRGC members barred from Canada after visa granted

April 30, 2026

Tuck Tape Expands Presence in Canadian Consumer Market with New and Rebranded Product Lineup

April 30, 2026

Biologics Outsourcing Market Research Report 2026: $42.43 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

April 30, 2026

Latest News

TTEC Recognized as a Major Contender in Everest Group’s 2026 Healthcare CXM Intelligent Operations PEAK Matrix® Assessment

April 30, 2026

Roblox’s daily users continue to drop as age-checks slow growth

April 30, 2026

Pharmaceutical API Manufacturing Market Research Report 2026: $347.49 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

April 30, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version